AR039645A1 - Fragmento polipeptido de una cadena gamma comun il-2 (c gamma c), adn que lo codifica, vector, celula, metodo para la produccion de dicho fragmento, anticuerpo que lo reconoce, molecula pequena capaz de inhibir la interaccion de nik-c gamma c, composiciones farmaceuticas que los comprende y su uso p - Google Patents

Fragmento polipeptido de una cadena gamma comun il-2 (c gamma c), adn que lo codifica, vector, celula, metodo para la produccion de dicho fragmento, anticuerpo que lo reconoce, molecula pequena capaz de inhibir la interaccion de nik-c gamma c, composiciones farmaceuticas que los comprende y su uso p

Info

Publication number
AR039645A1
AR039645A1 ARP030101363A ARP030101363A AR039645A1 AR 039645 A1 AR039645 A1 AR 039645A1 AR P030101363 A ARP030101363 A AR P030101363A AR P030101363 A ARP030101363 A AR P030101363A AR 039645 A1 AR039645 A1 AR 039645A1
Authority
AR
Argentina
Prior art keywords
fragment
interaction
nik
polypeptide fragment
gamma
Prior art date
Application number
ARP030101363A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL14921702A external-priority patent/IL149217A0/xx
Priority claimed from IL15218302A external-priority patent/IL152183A0/xx
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of AR039645A1 publication Critical patent/AR039645A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)

Abstract

Fragmento polipéptido de una cadena g común IL-2 (cgc) que incluye el dominio de enlace de NIK, o una muteína, proteína de fusión, derivado funcional, derivado permutado circularmente o fragmento de los mismos. ADN que codifica el fragmento polipéptido. Vector que consta del ADN y célula que consta del vector. Método para la producción de un fragmento polipéptido cgc que consiste en el cultivo de la célula anterior y que recoge el polipéptido producido. Anticuerpo, policlonal o monoclonal quimérico, totalmente humanizado, anti-anti-Id, intracuerpo o fragmento de los mismos, que reconoce específicamente y se une al fragmento polipéptido de cgc. Molécula pequena capaz de inhibir la interacción de NIK-cgc que se obtiene mediante detección de las moléculas preparadas por química combinatoria en un sistema de luciferasa. Composiciones farmacéuticas que constan del fragmento polipéptido, ADN, anticuerpo y molécula pequena anteriores. Uso de la cadena g común cgc IL-2 y moléculas relacionadas para la obtención de las composiciones para la modulación de las actividades de senal controlados por NIK.
ARP030101363A 2002-04-18 2003-04-21 Fragmento polipeptido de una cadena gamma comun il-2 (c gamma c), adn que lo codifica, vector, celula, metodo para la produccion de dicho fragmento, anticuerpo que lo reconoce, molecula pequena capaz de inhibir la interaccion de nik-c gamma c, composiciones farmaceuticas que los comprende y su uso p AR039645A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL14921702A IL149217A0 (en) 2002-04-18 2002-04-18 Derivatives of the il-2 receptor gamma chain, their preparation and use
IL15218302A IL152183A0 (en) 2002-10-08 2002-10-08 Derivatives of the il-2 receptor gamma chain, their preparation and use

Publications (1)

Publication Number Publication Date
AR039645A1 true AR039645A1 (es) 2005-03-02

Family

ID=29252551

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP030101364A AR039646A1 (es) 2002-04-18 2003-04-21 Fragmento de un polipeptido de nik, adn que lo codifica, vector, celula, metodo para la produccion de dicho fragmento, anticuerpo que lo reconoce, molecula pequena capaz de inhibir la interaccion de nik-c gamma c, composiciones farmaceuticas que los comprende y su uso para prepararlas.
ARP030101363A AR039645A1 (es) 2002-04-18 2003-04-21 Fragmento polipeptido de una cadena gamma comun il-2 (c gamma c), adn que lo codifica, vector, celula, metodo para la produccion de dicho fragmento, anticuerpo que lo reconoce, molecula pequena capaz de inhibir la interaccion de nik-c gamma c, composiciones farmaceuticas que los comprende y su uso p

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP030101364A AR039646A1 (es) 2002-04-18 2003-04-21 Fragmento de un polipeptido de nik, adn que lo codifica, vector, celula, metodo para la produccion de dicho fragmento, anticuerpo que lo reconoce, molecula pequena capaz de inhibir la interaccion de nik-c gamma c, composiciones farmaceuticas que los comprende y su uso para prepararlas.

Country Status (13)

Country Link
US (3) US7416730B2 (es)
EP (2) EP1499724B1 (es)
JP (2) JP4435574B2 (es)
AR (2) AR039646A1 (es)
AT (1) ATE521707T1 (es)
AU (2) AU2003222415B2 (es)
CA (2) CA2482387C (es)
CY (1) CY1111864T1 (es)
DK (1) DK1499729T5 (es)
ES (1) ES2415331T3 (es)
PT (1) PT1499729E (es)
SI (1) SI1499729T1 (es)
WO (2) WO2003087374A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158287A0 (en) * 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
CA2547459C (en) * 2003-11-30 2013-10-08 Yeda Research And Development Co. Ltd Modulators of nik-siva complex formation for treating immune disorders
US8034773B2 (en) * 2004-02-05 2011-10-11 Arizona Biomedical Research Commission Immunostimulatory compositions and uses thereof
IL166006A0 (en) * 2004-12-27 2006-01-15 Yeda Res & Dev Pharmaceutical compositions for treating diseases associated with nf-kb activity
US8226701B2 (en) 2007-09-26 2012-07-24 Trivascular, Inc. Stent and delivery system for deployment thereof
US8663309B2 (en) 2007-09-26 2014-03-04 Trivascular, Inc. Asymmetric stent apparatus and method
US8066755B2 (en) 2007-09-26 2011-11-29 Trivascular, Inc. System and method of pivoted stent deployment
EP2194921B1 (en) 2007-10-04 2018-08-29 TriVascular, Inc. Modular vascular graft for low profile percutaneous delivery
US8083789B2 (en) 2007-11-16 2011-12-27 Trivascular, Inc. Securement assembly and method for expandable endovascular device
US8328861B2 (en) 2007-11-16 2012-12-11 Trivascular, Inc. Delivery system and method for bifurcated graft
US8992595B2 (en) 2012-04-04 2015-03-31 Trivascular, Inc. Durable stent graft with tapered struts and stable delivery methods and devices
US9498363B2 (en) 2012-04-06 2016-11-22 Trivascular, Inc. Delivery catheter for endovascular device
JP6234446B2 (ja) * 2012-06-08 2017-11-22 アルカーメス，インコーポレイテッド ムチンドメインポリペプチドに連結された活性タンパク質を含む融合ポリペプチド
WO2018152371A1 (en) * 2017-02-15 2018-08-23 Fred Hutchinson Cancer Research Center In vivo gene therapy for immune deficiencies
WO2018191348A1 (en) * 2017-04-11 2018-10-18 University Of Maryland, Baltimore Compositions and methods for treating inflammation and cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US510259A (en) * 1893-12-05 Pavement
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
JP3255699B2 (ja) * 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
US7070972B1 (en) * 1995-01-13 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Janus family kinases and identification of immune modulators
UA71889C2 (uk) 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
US5843721A (en) * 1997-07-03 1998-12-01 Tularik Inc. Nucleic acids encoding human NIK protein
PT1161449E (pt) 1999-03-04 2007-10-12 Praecis Pharm Inc Moduladores de agregação do péptido beta-amilóide compreendendo d-aminoácidos

Also Published As

Publication number Publication date
AR039646A1 (es) 2005-03-02
AU2003222415A1 (en) 2003-10-27
CY1111864T1 (el) 2015-11-04
ES2415331T3 (es) 2013-07-25
US20050287144A1 (en) 2005-12-29
EP1499724A1 (en) 2005-01-26
EP1499729A1 (en) 2005-01-26
EP1499729B9 (en) 2012-03-14
WO2003087374A9 (en) 2005-01-27
EP1499729B1 (en) 2011-08-24
AU2003222415B2 (en) 2009-02-05
CA2482387C (en) 2015-03-03
WO2003087380A1 (en) 2003-10-23
DK1499729T3 (da) 2011-10-03
ATE521707T1 (de) 2011-09-15
US20090042796A1 (en) 2009-02-12
AU2003226607B2 (en) 2009-02-05
US7416730B2 (en) 2008-08-26
DK1499729T5 (da) 2011-12-05
CA2482387A1 (en) 2003-10-23
JP4435574B2 (ja) 2010-03-17
US8048847B2 (en) 2011-11-01
JP2005525113A (ja) 2005-08-25
EP1499724B1 (en) 2013-05-22
WO2003087374A1 (en) 2003-10-23
AU2003226607C1 (en) 2011-02-24
US8330026B2 (en) 2012-12-11
PT1499729E (pt) 2011-09-06
CA2482718C (en) 2014-08-19
SI1499729T1 (sl) 2011-11-30
CA2482718A1 (en) 2003-10-23
US20050272633A1 (en) 2005-12-08
JP2005530491A (ja) 2005-10-13
AU2003226607A1 (en) 2003-10-27
JP4435575B2 (ja) 2010-03-17

Similar Documents

Publication Publication Date Title
AR039645A1 (es) Fragmento polipeptido de una cadena gamma comun il-2 (c gamma c), adn que lo codifica, vector, celula, metodo para la produccion de dicho fragmento, anticuerpo que lo reconoce, molecula pequena capaz de inhibir la interaccion de nik-c gamma c, composiciones farmaceuticas que los comprende y su uso p
AR109355A2 (es) Moléculas de unión al receptor ox40 humano
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
EA200700847A1 (ru) Материалы, связывающие прионные белки, и способы их применения
CY1119024T1 (el) Καθαρισμος πρωτεϊνης
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
AR038568A1 (es) Anticuerpos anti-a beta y su uso
DK1615992T3 (da) Prionproteinbindende materialer og fremgangsmåder til anvendelse
CO5160384A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que comprende el mismo
CY1110923T1 (el) Συζυγη που περιλαμβανουν ενα αντισωμα ειδικο για την ed-β περιοχη της ινονεκτινης και η χρηση τους για τον εντοπισμο και την αντιμετωπιση ογκων
CY1116525T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
CY1115972T1 (el) Διμερικοι ιαρ αναστολεις
EA200870021A1 (ru) Человеческие моноклональные антитела к фукозил-gm1 и способы применения анти-фукозил-gm1 антител
DOP2002000507A (es) Anticuerpos cd40
CY1116364T1 (el) Αντισωματα της ip-10 και οι χρησεις αυτων
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
NO20073797L (no) Humane monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA)
Piermarini et al. Evidence against a direct interaction between intracellular carbonic anhydrase II and pure C-terminal domains of SLC4 bicarbonate transporters
BRPI0515079A (pt) marcadores imobilizados e métodos de detecção de prions conformacionalmente alterados
BRPI0512286B8 (pt) proteínas quiméricas inibidoras da angiogênese e o uso
NO20054836L (no) Nogo-reseptorbindingsprotein
CR9637A (es) Proteinas de enlace il-6
DE602006007967D1 (de) Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
DK1864131T3 (da) Naturlig ligand af G protein koblet receptor RCC356 og anvendelser deraf

Legal Events

Date Code Title Description
FC Refusal